<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04488432</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC19.0137</org_study_id>
    <nct_id>NCT04488432</nct_id>
  </id_info>
  <brief_title>Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant</brief_title>
  <acronym>ENDOCALLOGREFF</acronym>
  <official_title>Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic hematopoietic stem cell transplantations (allo-HSCT) is often indicated in&#xD;
      malignant hematologic diseases. Conditioning regimens, used to reduce the tumor burden and to&#xD;
      prevent transplant rejection, are based on chemotherapy alone or combined with total body&#xD;
      irradiation (TBI). Endocrine complications are frequent transplant-related side effects.&#xD;
      Investigators have been well described in children studies but less in adulthood.&#xD;
&#xD;
      The objective of this study is to assess retrospectively endocrine, bone and metabolic&#xD;
      disorders in adult patients, 12 months after allo-HSCT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients &amp; Methods Inclusion criteria are : patients treated with allo-HSCT from 2006 to 2016&#xD;
      for a malignant hematologic disease; adult and in complete remission at exploration.&#xD;
&#xD;
      Exclusion criteria are : anteriority of brain radiotherapy and prior HSCT.&#xD;
&#xD;
      Twelve months after HSCT, each patient underwent fasting measurement of IGF1, TSH, fT4, FSH,&#xD;
      LH, sex steroids, glycemia, insulin level, and lipid profile. Unless contraindication,&#xD;
      adrenal and growth hormone functions were assessed with insulin hypoglycemia test. A dual&#xD;
      X-ray absorptiometry was also performed.&#xD;
&#xD;
      Investigators will assess the prevalence of endocrine, bone and metabolic disorders 12 months&#xD;
      after allo-HSCT and describe some of their risk factors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2019</start_date>
  <completion_date type="Actual">November 27, 2019</completion_date>
  <primary_completion_date type="Actual">November 27, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adrenal insuffisiency prevalence</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>insulin hypoglycemia test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypothyroidism prevalence</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>fT4, TSH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth hormon Deficiency prevalence</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>insulin hypoglycemia test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premature ovarian failure prevalence</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>FSH, LH, estradiol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of elevated FSH in men</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>FSH, testosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of low bone mineral density</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>dual X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of obesity</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of dyslipidemia</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of hyperglycemia and insulin-resistance</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>glycemia and HOMA2-IR index</description>
  </secondary_outcome>
  <enrollment type="Actual">45</enrollment>
  <condition>Endocrine System Diseases</condition>
  <condition>Osteoporosis</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Adrenal Insufficiency</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with allo-HSCT after puberty from 2006 to 2016 in our University Hospital&#xD;
        of Brest, adult at the endocrine exploration.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients treated with allo-HSCT from 2006 to 2016 for a malignant hematologic disease&#xD;
&#xD;
          -  adult and in complete remission at exploration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  anteriority of brain radiotherapy&#xD;
&#xD;
          -  prior HSCT&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>CHRU de Brest - Endocrinology and Diabetology Department</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Adrenal Insufficiency</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

